Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
Keith C HayesDepartment of Physical Medicine and Rehabilitation, The University of Western Ontario, London, ON, CanadaAbstract: Dalfampridine extended release (ER) 10 mg is an oral tablet form of the potassium (K+) channel-blocking compounded dalfampridine, also known as fampridine, and chemically&a...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Dove Medical Press
2011-04-01
|
| Schriftenreihe: | Neuropsychiatric Disease and Treatment |
| Online-Zugang: | http://www.dovepress.com/impact-of-extended-release-dalfampridine-on-walking-ability-in-patient-a7273 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|